A The research considering Postoperative carcinoembryonic antigen (CEA) association with survival and oxaliplatin benefit in stage II colon cancer* has been discussed by Pr Richard ADAMS in poster discussion session
*Postoperative carcinoembryonic antigen (CEA) association with survival and oxaliplatin benefit in stage II colon cancer (CC): post hoc analysis of the MOSAIC trial
E. Auclin, T. Andre, J. Taieb, M. Banzi, J.-L. van Laethem, J. Tabernero, T. Hickish, A. De Gramont, D. Vernerey
B The research dealing with prediction of overall survival with 2nd-line (L2OS) chemotherapy (CT) in patients with advanced biliary tract cancer** has been awarded for best poster at ESMO 2018 in Munich.
**prediction of overall survival with 2nd-line (L2OS) chemotherapy (CT) in patients with advanced biliary tract cancer (aBTC): AGEO CT2BIL cohort update and international multicenter external validations
C. Neuzillet, A. Casadei Gardini, B. Brieau, C. Vivaldi, C. Smolenschi, G. Brandi, D. Tougeron, R. Filippi, A. Vienot, N. Silvestris, A.-L. Pointet, S. Murgioni, B. Rousseau, M. Scartozzi, L. Dahan, T. Boussaha, S. Crusz, A. Meurisse, A. Lievre, D. Vernerey
About Dewi VERNEREY
Dewi Vernerey is a research engineer in epidemiology and biostatistics who received a master’s degree cum laude from Joseph Fourier University (Grenoble, France) with a major in engineering statistics. He defended a PhD in epidemiology and statistics in 2016. His PhD research focused on statistical methodology for risk prediction and prognostic score construction in oncology and kidney transplantation.